To further expand on the targeted therapy approach, we reference the study by Schwaab et al. (2015) which examined the efficacy of ruxolitinib, in treating myeloid neoplasms with PCM1::JAK2 and BCR::JAK2 fusion genes. Here, PCM1 is linked to myeloid neoplasm.